Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics' stock has experienced significant volatility over the past six months, with a 215% increase but also a 22.32% decline over the past year. Key events include the release of topline data from the Phase 2 PIPE-307 VISTA trial, which did not meet its endpoints, third-quarter 2025 financial results, positive topline data from the Phase 1b PET trial of PIPE-791, second-quarter 2025 financial results, the stock reaching its all-time low of $3.35, and the company going public with an IPO offer price of $16.00 USD.

There is no information available regarding demand seasonality for Contineum Therapeutics' products and services, as the company is focused on clinical trials and its products are not yet commercially available.

Contineum Therapeutics, Inc. (CTNM) is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule therapies for neuroscience, inflammation, and immunology indications. Their pipeline includes PIPE-791 for IPF, PrMS, and chronic pain, PIPE-307 for depression and RRMS, and CTX-343, a peripherally restricted LPA1R antagonist.

Contineum Therapeutics, Inc. is headquartered in San Diego, California, United States, with clinical development activities indicating an international scope.

Contineum Therapeutics has generally received a "Moderate Buy" consensus rating from Wall Street analysts. Events affecting the company's reputation include stock price declines, positive topline data from the PIPE-791 Phase 1b PET trial, and negative results from the Phase 2 PIPE-307 VISTA trial for RRMS.

Contineum Therapeutics, Inc. has a diverse ownership structure. Institutions hold a significant portion of the company's stock, with 136 institutional owners and shareholders holding a total of 18,370,372 shares. Institutional ownership accounts for approximately 38% to 40.5% of the company. Hedge funds control about 12.1% to 15% of the shares, and private equity firms hold around 14.1% to 21%. The general public, primarily individual investors, holds approximately 24% to 31.5% ownership. Insiders collectively own about 1.79% to 11.30% of the company's shares. Major institutional owners include RA Capital Management, L.P., Johnson & Johnson Innovation - JJDC, Inc., Suvretta Capital Management, LLC, Franklin Resources Inc., Vanguard Group Inc., Balyasny Asset Management Llc., Fmr Llc, Sectoral Asset Management Inc., Perceptive Advisors Llc, Hillhouse Capital Advisors, Ltd., and Baker Bros. Advisors LP.